Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicinium in Non-Muscle Invasive Bladder Cancer
NCT04859751Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- scFv Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
A Phase 3 trial of oportuzumab monatox in non-muscle-invasive bladder cancer (NMIBC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
oportuzumab monatox
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04859751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859751.